Literature DB >> 31772989

A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy.

Bismarck C L Odei1, Dustin Boothe2, Sameer R Keole3, Carlos E Vargas3, Robert L Foote4, Steven E Schild3, Jonathan B Ashman3.   

Abstract

PURPOSE: Clinical trials (CTs) in proton beam therapy (PBT) are important for determining its benefits relative to other treatments. An analysis of PBT trials is, thus, warranted to understand the current state of PBT CTs and the factors affecting current and future trials.
MATERIALS AND METHODS: We queried the clinicaltrials.gov Website using the search terms: proton beam therapy, proton radiation, and protons. A total of 152 PBT CTs were identified. We used χ2 analysis and logistic regression to evaluate trial characteristics.
RESULTS: Most CTs were recruiting (n = 79; 52.0%), phase II (n = 95; 62.5%), open label (n = 134; 88.2%), single-group assignment (n = 84; 55.3%), and with primary treatment endpoints of safety and efficacy (n = 94; 61.8%). The primary treatment sites included gastrointestinal (n = 32; 21.1%), central nervous system (n = 31; 20.4%), lung (n = 21; 13.8%), prostate (n = 19; 12.5%), sarcoma (n = 15; 9.9%), and others (n = 24; 15.8%). Comparison studies between radiation modalities involved PBT and intensity-modulated photon therapy (n = 11; 7.2%), PBT and general photon therapy (n = 8; 5.3%), and PBT and carbon-ion therapy (n = 7; 4.6%). The PBT CTs underwent substantial growth after 2008 but now appear to be in decline. Nongovernmental institutions, comprising university centers, hospital systems, and research groups, have funded the greatest number of CTs (n= 106; 69.7%). The National Institutes of Health (NIH) were more likely to fund CTs involving the central nervous system (P = 0.02). Trials involving NIH funding were more likely to result in successful trial completion (P = 0.02).
CONCLUSION: Among PBT CTs, most were phase II trials, with a very few being phase III CTs. Funding of PBT CTs originating from industry or the NIH is limited. Recently, there has been a declining trajectory of newly initiated PBT trials. It is not yet clear whether this represents a true trend or just a pause in CT implementation. Despite multiple impediments to PBT CTs, the particle therapy community continues to work toward evidence generation. © Copyright 2017 International Journal of Particle Therapy 2016.

Entities:  

Keywords:  clinical trials; clinicaltrials.gov; proton beam therapy

Year:  2017        PMID: 31772989      PMCID: PMC6871603          DOI: 10.14338/IJPT-D-16-00030.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  22 in total

Review 1.  Impediments to Comparative Clinical Trials With Proton Therapy.

Authors:  James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-03       Impact factor: 7.038

2.  The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine.

Authors:  Joachim Widder; Arjen van der Schaaf; Philippe Lambin; Corrie A M Marijnen; Jean-Philippe Pignol; Coen R Rasch; Ben J Slotman; Marcel Verheij; Johannes A Langendijk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-09       Impact factor: 7.038

3.  Proton therapy expansion under current United States reimbursement models.

Authors:  John Kerstiens; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-27       Impact factor: 7.038

4.  Proton beam therapy - do we need the randomised trials and can we do them?

Authors:  Bengt Glimelius; Anders Montelius
Journal:  Radiother Oncol       Date:  2007-05-11       Impact factor: 6.280

5.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010.

Authors:  Robert M Califf; Deborah A Zarin; Judith M Kramer; Rachel E Sherman; Laura H Aberle; Asba Tasneem
Journal:  JAMA       Date:  2012-05-02       Impact factor: 56.272

6.  Reference pricing with evidence development: a way forward for proton therapy.

Authors:  Justin E Bekelman; Stephen M Hahn
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

7.  Particle Therapy at the "Tipping Point": An Introduction to the Red Journal's Special Edition.

Authors:  Anthony L Zietman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-05-01       Impact factor: 7.038

8.  Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report.

Authors:  Carmen Ares; Eugen B Hug; Antony J Lomax; Alessandra Bolsi; Beate Timmermann; Hans Peter Rutz; Jan C Schuller; Eros Pedroni; Gudrun Goitein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-20       Impact factor: 7.038

9.  Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.

Authors:  Herman Suit; Hanne Kooy; Alexei Trofimov; Jonathan Farr; John Munzenrider; Thomas DeLaney; Jay Loeffler; Benjamin Clasie; Sairos Safai; Harald Paganetti
Journal:  Radiother Oncol       Date:  2008-01-30       Impact factor: 6.280

Review 10.  The clinical case for proton beam therapy.

Authors:  Robert L Foote; Scott L Stafford; Ivy A Petersen; Jose S Pulido; Michelle J Clarke; Steven E Schild; Yolanda I Garces; Kenneth R Olivier; Robert C Miller; Michael G Haddock; Elizabeth Yan; Nadia N Laack; Carola A S Arndt; Steven J Buskirk; Vickie L Miller; Christopher R Brent; Jon J Kruse; Gary A Ezzell; Michael G Herman; Leonard L Gunderson; Charles Erlichman; Robert B Diasio
Journal:  Radiat Oncol       Date:  2012-10-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.